<DOC>
	<DOC>NCT02560220</DOC>
	<brief_summary>A phase- I clinical trial to determine safety and feasibilty of intravenous administration of mitomycin C-treated donor peripheral blood mononuclear cells in patients with chronic kidney disease stage KDIGO 4 or 5 (i.e. GFR 15-30 mL/min or &lt; 15 mL/min) who receive a kidney transplant from a living donor.</brief_summary>
	<brief_title>MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Chronic kidney disease stage KDIGO 4 or 5 First kidney transplant from a living donor Age â‰¥ 18 years ABO compatible CDCPRA &lt; 20% No donorspecific antibodies Negative CDC and ELISA crossmatch Immunosuppression with cyclosporin A, ECMPS and methylprednisolone Informed consent Adequate contraception (women with child bearing potential) Psychiatric disorder Heart failure (NYHA III or IV) Severe liver disease Active hepatitis B or C or HIV infection Active bacterial, fungal or viral disease Malignancy or malignancy in the last 5 years before screening Preexisting immunosuppression Vaccination with a live vaccine in the last 3 months before screening S/p splenectomy Substance abuse Pregnancy or lactation Women: Child/pregnancy with the intended donor Allergy against the investigational drug or part of it Other diseases that prohibit participation in the study (in the opinion of the investigator) Participation in an other interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>